Review
Medicine, General & Internal
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Gennaro Palmiotti, Francesco Massari
Summary: In urothelial carcinoma patients, immune checkpoint inhibitors used as neoadjuvant treatment may lead to promising pathologic complete response rates. PD-L1 expression status may serve as a predictive biomarker.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Muhammet Ozer, Charan Thej Reddy Vegivinti, Masood Syed, Morgan E. E. Ferrell, Cyndi Gonzalez Gomez, Svea Cheng, Jennifer Holder-Murray, Tullia Bruno, Anwaar Saeed, Ibrahim Halil Sahin
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of mismatch repair-deficient (MMR-D)/microsatellite instability-high (MSI-H) gastrointestinal cancers. These cancers have a high mutation burden and generate mutation-associated neoantigens (MANAs). ICIs activate T-cell immunity against these cancers, leading to significant antitumor activity. The use of ICIs as neoadjuvant therapy shows great promise, as demonstrated by deep clinical and pathological responses in clinical trials.
Article
Biotechnology & Applied Microbiology
Virginia Ferraresi, Sabrina Vari
Summary: The success of immunotherapy and targeted therapy for metastatic melanoma has generated interest in adjuvant therapy for high-risk stage III melanoma. Immune checkpoint inhibitors activate tumor-reactive T cells to potentially prevent relapses.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Oncology
Yan Hu, Si-Ying Ren, Ruo-Yao Wang, Chao Zeng, Ji-Na Li, Peng Xiao, Fang Wu, Feng-Lei Yu, Wen-Liang Liu
Summary: The study demonstrated that preoperative administration of chemoimmunotherapy for patients with resectable NSCLC is safe and feasible, with the majority of patients experiencing no serious complications or adverse reactions during treatment.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Mairi W. Lucas, Catherine M. Kelly
Summary: The neoadjuvant setting provides great opportunities for translational research and drug development. The use of pathological complete response (pCR) as a surrogate endpoint has led to the widespread use of neoadjuvant treatment. Optimal neoadjuvant therapies are determined by their ability to achieve high pCR rates. Triple negative breast cancer (TNBC) has predicted pCR rates ranging from 35% to 48% with sequential taxane/anthracycline regimens, and rates of 55% with the addition of a platinum agent. The addition of immune checkpoint inhibitors has further increased pCR rates. In HR-positive, HER2-negative breast cancer, the role of neoadjuvant chemotherapy is less clear. HR-positive cancers, especially low-grade tumors, have the least chance of achieving pCR after neoadjuvant chemotherapy. Standard adjuvant anthracycline/taxane regimens are appropriate for high-risk HR-positive, HER2-negative breast cancer. Optimum endocrine therapy is the standard-of-care regardless of pCR. Genomic signatures are not routinely used in the neoadjuvant setting. The monarchE trial showed that high-risk patients who meet the criteria can benefit from adjuvant abemaciclib in addition to endocrine therapy. Germline BRCA mutation patients should be considered for adjuvant olaparib therapy based on the OlympiA trial. This article reviews neoadjuvant clinical trials that guide optimal treatment options for TNBC and HR-positive, HER2-negative breast cancer.
CANCER MANAGEMENT AND RESEARCH
(2022)
Review
Engineering, Biomedical
Mengying He, Tao Yang, Yuhan Wang, Mengyuan Wang, Xingye Chen, Dawei Ding, Yiran Zheng, Huabing Chen
Summary: Immune checkpoint blockade therapy has shown potential efficacy in various cancers, but its effectiveness is limited when used alone. Studies have demonstrated that combining ICBT with other treatment modalities such as chemotherapy, radiotherapy, and phototherapy can enhance therapeutic outcomes. However, there are still challenges and potential issues that need to be addressed in the research on ICBT-based synergistic therapies.
ADVANCED HEALTHCARE MATERIALS
(2021)
Review
Oncology
Alex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, Giulio Metro, Patrick Forde, Alfredo Addeo
Summary: ICIs have become crucial in the treatment of NSCLC, and neoadjuvant therapy may bring about a paradigm shift. However, determining the benefits of neoadjuvant therapy is challenging. This review discusses the role and impact of neoadjuvant therapy, along with related data and trials.
CANCER TREATMENT REVIEWS
(2022)
Review
Oncology
Mengyuan Shi, Yongkang Chen, Dengbo Ji
Summary: Neoadjuvant chemoradiotherapy (nCRT) is recommended for the treatment of locally advanced rectal cancer. This review focuses on the immunological mechanism involved in nCRT, the clinical efficacy, the immunological effect of different combined strategies, and the impact of nCRT on tumor immunity. It aims to provide clues for optimal neoadjuvant therapy options that maximize efficacy and minimize side effects.
Article
Chemistry, Multidisciplinary
Qinghua Wu, Yang Chen, Qing Li, Junmeng Chen, Junfeng Mo, Ming Jin, Qianzhan Yang, Loris Rizzello, Xiaohe Tian, Lei Luo
Summary: This study investigates the timing of intervention with immune checkpoint inhibitors (ICI) after photodynamic therapy (PDT) and its impact on tumor efficacy. A tumor-targeting nanomedicine encapsulating indocyanine green is prepared, and ICI is administered 5 days after PDT. The optimal combination significantly suppresses tumor growth and eliminates metastasis. This research provides theoretical guidance for enhancing immune checkpoint blockade therapy (ICBT) through intervention timing.
Article
Chemistry, Multidisciplinary
Jia-Bin Wang, Qing-Zhu Qiu, Qiao-Ling Zheng, Ya-Jun Zhao, Yu Xu, Tao Zhang, Shuan-Hu Wang, Quan Wang, Qin-Wen Jin, Yin-Hua Ye, Ping Li, Jian-Wei Xie, Jian-Xian Lin, Jun Lu, Qi-Yue Chen, Long-Long Cao, Ying-Hong Yang, Chao-Hui Zheng, Chang-Ming Huang
Summary: In this study, a gastric cancer immunophenotypic score (IPS) was constructed based on the tumor microenvironment classification, which can predict the effectiveness of immune checkpoint inhibitor therapy. The IPS provides a practical reference for implementing neoadjuvant ICI therapy for patients with gastric cancer.
Review
Biochemistry & Molecular Biology
Ivana De Risi, Angela Monica Sciacovelli, Michele Guida
Summary: Immune checkpoint inhibition (ICI) has significantly improved the survival of patients with metastatic melanoma (MM), but it also comes with new and sometimes irreversible toxicities. There is currently no consensus on the optimal duration of ICI therapy, and controlled prospective studies are needed.
Article
Pharmacology & Pharmacy
Carolina de Aguiar Ferreira, Pedram Heidari, Bahar Ataeinia, Nicoleta Sinevici, Alyssa Granito, Hritik Mahajan Kumar, Eric Wehrenberg-Klee, Umar Mahmood
Summary: Immune checkpoint inhibitors (ICI) have greatly impacted cancer management, but heterogeneous patient response and ICI resistance are common. This study explores the combination of targeted radionuclide therapy with ICI and demonstrates improved treatment outcomes, including curative response and increased overall survival.
Article
Oncology
Jiale Gao, Xiao Zhang, Zhengyang Yang, Jie Zhang, Zhigang Bai, Wei Deng, Guangyong Chen, Rui Xu, Qi Wei, Yishan Liu, Jiagang Han, Ang Li, Gang Liu, Yi Sun, Dalu Kong, Hongwei Yao, Zhongtao Zhang
Summary: This study aims to explore the safety and efficacy of long-course chemoradiotherapy combined with concurrent tislelizumab as a neoadjuvant treatment regimen for patients with locally advanced rectal cancer. The results showed that this regimen has favorable safety and efficacy, and does not increase the complication rate of surgery, achieving a high rate of pathological complete remission.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Guillermo Suay, Juan-Carlos Garcia-Canaveras, Francisco Aparisi, Agustin Lahoz, Oscar Juan-Vidal
Summary: Immune checkpoint inhibitors have revolutionized the treatment of metastatic non-small cell lung cancer. Women tend to have better responses to ICIs, possibly due to their more proficient immune system. ICIs have also shown promising results as neoadjuvant treatments. This study examines the role of sex in modulating responses to ICIs.
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiao Bao, Dongliang Bian, Xing Yang, Zheming Wang, Mingdong Shang, Gening Jiang, Jingyun Shi
Summary: This study aimed to explore the predictive value of IVIM-DWI and DKI quantitative parameters for NCIT response in NSCLC patients. The independent predictors for NCIT response were found to be the pre-NCIT D value and post-NCIT K-app value. The combined IVIM-DWI and DKI prediction model showed the best performance.
EUROPEAN RADIOLOGY
(2023)
Letter
Pathology
Tomoaki Naka, Taiki Hashimoto, Teruhiko Yoshida, Yasushi Yatabe, Shigeki Sekine
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2023)
Editorial Material
Oncology
Masaya Yotsukura, Yuji Muraoka, Yukihiro Yoshida, Kazuo Nakagawa, Kouya Shiraishi, Takashi Kohno, Yasushi Yatabe, Shun-ichi Watanabe
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Pathology
Naoki Kojima, Taisuke Mori, Toru Motoi, Eisuke Kobayashi, Masayuki Yoshida, Yasushi Yatabe, Hitoshi Ichikawa, Akira Kawai, Kan Yonemori, Cristina R. Antonescu, Akihiko Yoshida
Summary: This study investigated the expression of CD30 in mesenchymal tumors with kinase gene fusions using immunohistochemistry. The results showed that CD30 was expressed in a significant number of NTRK-rearranged tumors and tumors with BRAF, RAF1, or RET fusions. The frequent expression of CD30 enhances the shared phenotype of spindle-cell tumors with kinase gene fusions.
Article
Oncology
Yasuhiro Tsutani, Jonathan W. Goldman, Sanja Dacic, Yasushi Yatabe, Margarita Majem, Xiangning Huang, Allen Chen, Toon van der Gronde, Jie He
Summary: ADAURA2 is a clinical study designed to evaluate the efficacy of adjuvant osimertinib compared to placebo in patients with completely resected EGFR mutation-positive non-small cell lung cancer. The study aims to assess disease-free survival in high-risk patients, with secondary endpoints including overall survival and CNS disease-free survival.
CLINICAL LUNG CANCER
(2023)
Article
Cell Biology
Hirokazu Sugino, Shintaro Iwata, Kaishi Satomi, Taisuke Mori, Sumihito Nobusawa, Toshiteru Nagashima, Yuko Matsushita, Yasushi Yatabe, Koichi Ichimura, Akira Kawai, Akihiko Yoshida
Summary: A new rare form of sarcoma called extraskeletal myxoid chondrosarcoma (EMC) with distinct histology and NR4A3 gene fusion was discovered in this study. This type of tumor may express keratin and has differences in histology compared to similar soft-tissue myoepithelial tumors. NR4A3 genetic analysis should be conducted for tumors with keratin expression to avoid misdiagnosis.
Article
Oncology
Yoichi Naito, Saori Mishima, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama, Motohiro Kato, Hirotsugu Kenmotsu, Yasuhiro Kodera, Keigo Komine, Takafumi Koyama, Osamu Maeda, Mitsuru Miyachi, Hiroshi Nishihara, Hiroyuki Nishiyama, Shouichi Ohga, Wataru Okamoto, Eiji Oki, Shigeru Ono, Masashi Sanada, Ikuo Sekine, Tadao Takano, Kayoko Tao, Keita Terashima, Katsuya Tsuchihara, Yasushi Yatabe, Takayuki Yoshino, Eishi Baba
Summary: This article discusses the efficacy of tropomyosin receptor kinase (TRK) inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors and provides 14 clinical recommendations for proper NTRK testing and treatment selection.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Saori Mishima, Yoichi Naito, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama, Motohiro Kato, Hirotsugu Kenmotsu, Yasuhiro Kodera, Keigo Komine, Takafumi Koyama, Osamu Maeda, Mitsuru Miyachi, Hiroshi Nishihara, Hiroyuki Nishiyama, Shouichi Ohga, Wataru Okamoto, Eiji Oki, Shigeru Ono, Masashi Sanada, Ikuo Sekine, Tadao Takano, Kayoko Tao, Keita Terashima, Katsuya Tsuchihara, Yasushi Yatabe, Takayuki Yoshino, Eishi Baba
Summary: The development of novel antitumor agents and biomarkers has improved survival in different tumor types. Immune checkpoint inhibitors have shown efficacy in patients with TMB-H solid tumors, leading to the need for guidelines prioritized for these patients. This guideline provides recommendations for properly testing TMB and selecting patients who can benefit from immunotherapy.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Yu Okubo, Yasushi Yatabe
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Medicine, General & Internal
Hidenori Suzuki, Gaku Takano, Satoshi Tsukushi, Masashi Ando, Yasushi Yatabe, Takeshi Kodaira, Daisuke Nishikawa, Shintaro Beppu, Yasuhisa Hasegawa, Nobuhiro Hanai
Summary: The present study aimed to investigate the relationship between age at surgery and survival outcomes in patients with sarcoma in the head and neck. A total of 26 patients who underwent surgery for head and neck sarcoma from 2003 to 2017 were included. Patients who did not receive chemotherapy were significantly older at the time of surgery. Receiver operating curve analysis determined 55 years as the cutoff age for predicting death. Older age was associated with shorter overall, disease-specific, local recurrence-free, and disease-free survival rates. Multivariate analysis using Cox's proportional hazards model adjusted for chemotherapy (absence/presence) showed that age (>= 55 years/<55 years) was correlated with shorter overall survival. In conclusion, older age predicts worse overall survival in patients with head and neck sarcoma.
Review
Oncology
Teruhiko Yoshida, Yasushi Yatabe, Ken Kato, Genichiro Ishii, Akinobu Hamada, Hiroyuki Mano, Kuniko Sunami, Noboru Yamamoto, Takashi Kohno
Summary: The journey to implement cancer genomic medicine began in the 1980s, leading to the development of targeted therapies. The National Cancer Center of Japan has made significant contributions to this field. The future of cancer genomic medicine is predicted to involve the development of biobanks, introduction of new technologies, fast translational research, collaborations, and investment in personalized preventive medicine.
CANCER BIOLOGY & MEDICINE
(2023)
Review
Oncology
Tony Kiat Hon Lim, Ferdinandos Skoulidis, Keith M. Kerr, Myung-Ju Ahn, Joshua R. Kapp, Fernando A. Soares, Yasushi Yatabe
Summary: KRAS is the most commonly mutated oncogene in advanced NSCLC, and the approval of KRAS G12C-selective inhibitors has made it a druggable target. Real-world evidence shows geographic differences in KRAS G12C prevalence, and co-mutations with other genes are also common. Testing and reporting of KRAS G12C should be included in routine biomarker testing before first-line therapy.
Article
Oncology
Kanako Nishimatsu, Yuji Matsumoto, Jumpei Kashima, Tatsuya Imabayashi, Keigo Uchimura, Hideaki Furuse, Ken Masuda, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Takaaki Tsuchida, Yuichiro Ohe, Yasushi Yatabe
Summary: This study compared the differences in immunohistochemistry (IHC) results between cryobiopsy and conventional biopsy specimens of lung cancer tissue. The results showed that freezing and thawing associated with cryobiopsy had virtually no effect on the IHC results, suggesting that cryobiopsy specimens are ideal for precision medicine and translational research.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Takaki Akamine, Kazuo Nakagawa, Kimiteru Ito, Hirokazu Watanabe, Masaya Yotsukura, Yukihiro Yoshida, Yasushi Yatabe, Masahiko Kusumoto, Shun-Ichi Watanabe
Summary: We evaluated the potential of preoperative fluorine-18-fluorodeoxyglucose positron emission tomography to predict invasive thymic epithelial tumours in patients with computed tomography-defined clinical stage I thymic epithelial tumours <5 cm in size who are generally considered to be candidates for minimally invasive approaches.
INTERDISCIPLINARY CARDIOVASCULAR AND THORACIC SURGERY
(2023)
Review
Cell Biology
Keith M. Kerr, Lukas Bubendorf, Fernando Lopez-Rios, Farah Khalil, Sinchita Roy-Chowdhuri, Philippe Joubert, Arndt Hartmann, Elena Guerini-Rocco, Yasushi Yatabe, Paul Hofman, Wendy A. Cooper, Sanja Dacic
Summary: Many patients with non-small cell lung cancer do not receive guideline-recommended, biomarker-directed therapy. Optimized tissue management is crucial for the protection and utilization of limited tissue resources, enabling accurate molecular profiling and treatment selection.
Review
Oncology
Shinkichi Takamori, Yasushi Yatabe, Atsushi Osoegawa, Keiju Aokage, Hiroshige Yoshioka, Tomohiro Miyoshi, Takahiro Mimae, Makoto Endo, Aritoshi Hattori, Masaya Yotsukura, Tetsuya Isaka, Mitsuhiro Isaka, Tomohiro Maniwa, Ryu Nakajima, Shun-ichi Watanabe, Lung Canc Surgical Study Grp LCSSG, Japan Clinical Oncology Grp JCOG
Summary: Salivary gland-type lung tumors (SGT), primarily mucoepidermoid carcinoma and adenoid cystic carcinoma, are rare and present with symptoms of bronchial obstruction. Surgical resection with lymphadenectomy is recommended, and radiation therapy varies by subtype. The diagnosis and treatment of SGT remain challenging.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)